# CheckMate 73L (NCT04026412)

> A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab; nivolumab
- Indication: previously untreated locally advanced stage III NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04026412
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Non-Small Cell Lung Cancer (NSCLC)
- Interventions: nivolumab; ipilimumab; durvalumab
- Enrollment: 925
- Primary outcome: Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)

## Questions raised in the commentary

_Automated from the 32 newest of 34 indexed sources (Oct 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- How immunotherapy should be timed relative to chemoradiation
- How immunotherapy and chemoradiation interact biologically
- Whether concurrent immunotherapy affects pneumonitis and other toxicity risks

Also discussed: durvalumab consolidation.

## Indexed commentary on CheckMate 73L so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- Podcasts: 10
- YouTube: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-73l-nct04026412

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04026412", "email": "<work email>"}; the inbox owner confirms by the emailed link.